Treatment of depression with citalopram, fluoxetine, paroxetine, sertraline, and venlafaxine in managed care: Part 2 - Patient comorbidities and coprescribed therapies

Drug Benefit Trends

Volumn 14, Issue 8, 2002, Pages 33-40

  Valuck, Robert J ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Comorbidities; Depression; Pharmacotherapy; SSRIs

Indexed keywords

AMFEBUTAMONE; ANTICONVULSIVE AGENT; ANXIOLYTIC AGENT; CENTRAL STIMULANT AGENT; CITALOPRAM; CODEINE; FLUOXETINE; LITHIUM; METOPROLOL; MIRTAZAPINE; NEFAZODONE; NEUROLEPTIC AGENT; PAROXETINE; PHENOBARBITAL; PHENYTOIN; PROPRANOLOL; SEDATIVE AGENT; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; VERAPAMIL; WARFARIN; ZOLPIDEM;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DOCTOR PATIENT RELATION; DRUG COST; DRUG EFFICACY; FEMALE; HEALTH CARE PLANNING; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; MEDICAL DECISION MAKING; MENTAL DISEASE; OUTCOMES RESEARCH; POPULATION RESEARCH; PRESCRIPTION; UNITED STATES;

EID: 0036677778     PISSN: 10805826     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Current issues in the treatment of major depression
2. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: Results from the National Comorbidity Survey
3. The economic burden of depression in 1990
4. A critical review of selected pharmacoeconomic analses of antidepressant therapy
5. The functioning and well-being of depressed patients: Results from the Medical Outcomes Study
6. Pharmacoeconomic issues in the treatment of depression
7. Selective serotonin reuptake inhibitors: Meta-analysis of efficacy and acceptability
8. The benefits and risks of 5-HT uptake inhibitors in depression
9. Episode treatment groups: An illness classification and episode building system, part 1
10. Episode treatment groups: An illness classification and episode building, system, part 2
11. Treatment of depression with citalopram, fluoxetine, paroxetine, sertraline, and venlafaxine in managed care: Part 1 - Drug selection, dosing, and utilization
12. Channeling of three newly introduced antidepressants to patients not responding satisfactorily to previous treatment
13. Using databases for studying and comparing health care costs and resource use